Hudson Bay Capital Management
TVTX icon

Hudson Bay Capital Management’s Travere Therapeutics TVTX Stock Holding History

Hudson Bay Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Sell
44,200
-856,100
-95% -$25.6M ﹤0.01% 841
2025
Q4 		$34.4M Buy
900,300
+584,000
+185% +$19M 0.11% 163
2025
Q3 		$7.56M Buy
+316,300
New +$5.95M 0.03% 430

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hudson Bay Capital Management's TVTX Position: Q1 2026 in Review

Hudson Bay Capital Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 6,520 shares worth $194K. The stake represents ﹤0.01% of the portfolio and ranks #1109 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in TVTX as recently as Q3 2024.

Hudson Bay Capital Management first reported a position in TVTX in Q2 2019 and has held it in 5 quarters since. The position peaked at $6.82M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Hudson Bay Capital Management held 6,520 shares of Travere Therapeutics worth $194K as of Q1 2026.
  • Travere Therapeutics was a new Hudson Bay Capital Management position in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q1 2026, its #1109 holding.
  • Hudson Bay Capital Management first reported a position in Travere Therapeutics in Q2 2019 and has held it in 5 quarters since.
  • Hudson Bay Capital Management's Travere Therapeutics position peaked at $6.82M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.